The Most Spoken Article on Fibrillar Absorbable Topical Hemostat

The Most Spoken Article on Fibrillar Absorbable Topical Hemostat

Blog Article


Fibrillar Absorbable Hemostat: A Promising Aid for Bleeding Control in Colorectal Tumors

Colorectal cancer, among the most widespread cancers worldwide, typically needs advanced treatment modalities to accomplish optimal results. Amongst these, endoscopic submucosal dissection (ESD) has emerged as an appealing method for the early-stage management of colorectal tumors. However, the procedure's success can be tempered by postoperative complications such as postponed bleeding and perforation, along with the difficulty of managing big mucosal defects. Furthermore, exposure to gastrointestinal flora increases the risk of bacteremia and endotoxemia. In the mission for much safer and more effective services, researchers and clinicians are continuously exploring alternative approaches. Fibrillar absorbable hemostat such as Surgicel ® Fibrillar ™ (Ethicon), nevertheless, emerges as a game-changer provides a multifaceted approach to post-ESD care, supplying both hemostatic support and localized bactericidal results.

A noteworthy item in this realm is Surgi-ORC ® Fibril from Aegis Lifesciences, including the following key qualities:

Key Features of Surgi-ORC ® Fibril:

• Lightweight, tufted, soft and layered structure
• Provides high versatility and conformability to surgical sites
• Suitable for irregular shaped wounds and hard-to-reach areas
• Bactericidal properties
• Soft, layered product conforms and "melts in" to bleeding tissue
• Completely absorbable
• 7 layers fibrillose fabric
• Designed for hemostasis in

How does Surgi-ORC ® Fibril Work?
Surgi-ORC ® Fibrilis made up of oxidized regenerated cellulose, which, upon contact with blood, swells into a gelatinous mass, aiding in embolisms development and preventing additional bleeding. Moreover, its low pH of 3.4 exhibitions powerful bactericidal properties, reducing the risk of infection considerably.

Clinical Study Results:

A clinical study was conducted at the University of Soonchunhyang Hospital in Bucheon, Korea, sheds light on the efficiency of Surgicel ® Fibrillar ™ in colorectal ESD. In a cohort of 49 patients, Surgicel ® Fibrillar ™ was effectively applied Fibrillar Absorbable Hemostat to cover the entire mucosal defect following ESD, without any Surgicel-related problems. Extremely, none of the patients in the Surgicel group experienced delayed bleeding or perforation, marking a considerable enhancement over standard ESD techniques. Furthermore, Surgicel ® Fibrillar ™ was connected with much shorter hospital stays and lower inflammatory markers, suggesting quicker recovery and enhanced postoperative results.

Fig. 1: A) Lateral spreading tumor; B) Dissected colon LST by colon endoscopic submucosal dissection.; C) Surgicel was positioned onto the mucosal defect to cover the whole mucosal defect; D) Surgicel swelled into a gelatinous mass [1]


In the world of colorectal cancer treatment, every advancement brings us closer to our ultimate goal: improving patient outcomes and enhancing quality of life. Fibrillar absorbable hemostat represents a pivotal milestone in this journey, providing a potent combination of hemostatic efficacy and antimicrobial security. As we continue to push the limits of innovation, let us embrace the transformative potential of Fibrillar absorbable hemostat and embark on a path towards safer, more reliable colorectal endoscopic resection.


[1] Myung YS, Ko BM, Han JP, Hong SJ, Jeon SR, Kim JO, Moon JH, Lee MS. Effectiveness of Surgicel® (Fibrillar) in patients with colorectal endoscopic submucosal dissection. Surgical endoscopy. 2016 Apr;30:1534-41. DOI:10.1007/s00464-015-4369-5

Article Tags: Fibrillar Absorbable Hemostat, Fibrillar Absorbable Topical Hemostat.

Report this page